TY - JOUR
T1 - Sugammadex
T2 - A comprehensive review of the published human science, including renal studies
AU - Partownavid, Parisa
AU - Romito, Bryan T.
AU - Ching, Willy
AU - Berry, Ashley A.
AU - Barkulis, Charles T.
AU - Nguyen, Kim Ngan P.
AU - Jahr, Jonathan S.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.
AB - Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a "can't ventilate, can't intubate" crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.
KW - cyclodextrins
KW - muscle relaxant
KW - muscle relaxant reversal
KW - rocuronium
KW - selective relaxant binding agents
KW - sugammadex
KW - vecuronium
UR - http://www.scopus.com/inward/record.url?scp=84937550719&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937550719&partnerID=8YFLogxK
U2 - 10.1097/MJT.0000000000000103
DO - 10.1097/MJT.0000000000000103
M3 - Review article
C2 - 25299638
AN - SCOPUS:84937550719
SN - 1075-2765
VL - 22
SP - 298
EP - 317
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
IS - 4
ER -